Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Antengene
AddedJul 2, 2026
UpdatedJul 2, 2026
Antengene

Antengene

Public

Antengene (SEHK:6996) develops and commercializes innovative oncology therapies for Asia-Pacific patients.

HQ
Shanghai, Shanghai, CN
Founded
2017
Overview
Compare
Fundraising
Employees
News
Website

Antengene Corporation Limited (SEHK: 6996.HK) is a global R&D-driven commercial-stage biopharmaceutical company founded in April 2017 in Shanghai, China. It focuses on first-in-class and best-in-class therapeutics for hematological malignancies and solid tumors, with vision to treat patients beyond borders in Asia-Pacific markets and globally.

Key commercial asset XPOVIO (selinexor) is approved in 10 APAC markets. Proprietary AnTenGager TCE 2.0 platform advances pipeline including ATG-022 in pivotal Phase III. Backed by Qiming as lead Series A investor, the company listed on HKEX in 2020 raising ~HK$2.79 billion with HQ and ops in China and APAC.

Antengene - Similar Companies

Seagen logo

Seagen

seagen.com

Athenex logo

Athenex

CellType logo

CellType

celltype.com

Antios Therapeutics logo

Antios Therapeutics

argenx logo

argenx

OncoSenX logo

OncoSenX

oncosenx.com

BeOne Medicines logo

BeOne Medicines

beigene.com

Agenus logo

Agenus

agenusbio.com

Aigene logo

Aigene

a-i-gene.com

Antoxerene logo

Antoxerene

Angiex logo

Angiex

angiex.com

ApoGen Biotechnologies logo

ApoGen Biotechnologies

apogenbiotech.com

Neoantigenics logo

Neoantigenics

Affigen logo

Affigen

affigen.com

TigerGene logo

TigerGene

Antengene - Quick Facts

Who are Antengene's competitors?

Companies similar to Antengene include Seagen, Athenex, CellType and Antios Therapeutics.

When was Antengene founded?

Antengene was founded in 2017.

Where is Antengene's headquarters located?

Antengene's headquarters is located in Shanghai, Shanghai, CN.

When was Antengene's last funding round?

Antengene's most recent funding round was for $2.8B (USD) in November 2020.

How much has Antengene raised to-date?

As of Nov 20, 2020, Antengene has raised a total of $3B (USD).